Gen XY Updates from GlobeNewswire
2024-09-09T21:15:58Z
DOYLESTOWN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today...
2024-09-09T21:00:00Z
Late-breaking data at WCLC show Libtayo monotherapy nearly doubled median overall survival and reduced the risks of death and disease progression by 41% and 50%, respectively, compared to chemotherapy
2024-09-09T20:47:16Z
If approved, neffy 1 mg will be the first and only needle-free epinephrine treatment available for younger school-aged children
2024-09-09T20:45:07Z
BEDFORD, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on September 3, 2024, Anika...
2024-09-09T20:34:20Z
CAMBRIDGE, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced...
2024-09-09T20:16:45Z
LONDON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Treos Bio announced the results of a meta-analysis from three clinical trials evaluating its investigational off-the-shelf immunotherapy, PolyPEPI1018, for the treatment of microsatellite...
2024-09-09T20:06:00Z
September 18th Event in New York City to Include a Review of the Opportunity for Investigational Therapy IMNN-001 (IL-12) to Treat Advanced Ovarian Cancer and Clinical Development Timeline
2024-09-09T20:05:31Z
-- Recorded First Quarter Revenue of $40.2 Million ---- Signed $66 Million in Net New Business, Resulting in Backlog of $219 Million --
2024-09-09T20:05:00Z
DOYLESTOWN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today...
2024-09-09T20:05:00Z
SUNNYVALE, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced...
2024-09-09T20:05:00Z
DUBLIN, Ireland, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today provided...
2024-09-09T20:01:00Z
FOSTER CITY, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to...
2024-09-09T20:01:00Z
Abivax presents first-half 2024 financial results
2024-09-09T20:01:00Z
SAN MATEO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- TriArm Therapeutics (“TriArm” or the “Company”), a clinical-stage, next-generation cell therapy company leveraging its global presence and core non-viral platform to...
2024-09-09T20:00:00Z
TAMPA, Fla., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the...
2024-09-09T18:58:30Z
HOLLYWOOD, Fla., Sept. 09, 2024 (GLOBE NEWSWIRE) -- As the nation recognizes National Recovery Month, Recovery First Treatment Center has launched a virtual evening Intensive Outpatient Program (IOP) to help...
2024-09-09T16:05:00Z
81.8% ORR by BICR and 63.6% confirmed ORR by BICR at the 240 mg dose; 46.2% confirmed ORR in CNS Metastases
2024-09-09T15:45:00Z
Boehringer Ingelheim reports positive results from a Phase Ib primary analysis of Cohort 1 of the Beamion LUNG-1 trial evaluating zongertinib (BI 1810631) in pre-treated patients with advanced non-small cell...
2024-09-09T15:01:00Z
Company announcement – No. 44 / 2024
2024-09-09T14:52:30Z
BERKELEY HEIGHTS, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it...
2024-09-09T14:30:00Z
Norton Healthcare, Norton Children’s to become a hub for isolating high-quality human islet cells for diabetes research and transplant
2024-09-09T14:22:00Z
Expert Capablites of Senior Vet-Tech to Help Drive Greater Adoption of Spryng as Breakthrough Treatment of Osteoarthritis for Companiaon Animals
2024-09-09T14:10:38Z
Bagsværd, Denmark, 9 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament...
2024-09-09T14:01:52Z
MIAMI, Sept. 09, 2024 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc., a leading clinical-stage biotechnology company dedicated to the advancement of innovative therapies for Alzheimer's disease, proudly announces the recent appointment...
2024-09-09T13:55:01Z
Novo Nordisk A/S – Share repurchase programme
2024-09-09T13:31:09Z
Early Pilot Study Data from Veteran Volunteers is Compelling - Part B
2024-09-09T13:00:07Z
The members-only luxury vacation club boasts a high Net Promoter Score of 71, a metric for measuring customer satisfaction—one of the highest in the travel industry.
2024-09-09T13:00:00Z
PALO ALTO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management...
2024-09-09T13:00:00Z
Company plans to launch multiple direct-from-blood diagnostics over the next 15 months for antimicrobial resistance, pediatric Candida infections, Lyme disease, and Candida auris
2024-09-09T12:40:20Z
ST. LOUIS, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman...
2024-09-09T12:30:35Z
SCOTTSDALE, Ariz., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing...
2024-09-09T12:30:08Z
SOLANA BEACH, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide)...
2024-09-09T12:30:00Z
Collaboration Aims to Expedite the Development of Critical Solutions for Public Health Threats, Including Pandemic Preparedness and Emerging Infectious Diseases
2024-09-09T12:30:00Z
Purchases Signal Leadership Confidence and Commitment to Company
2024-09-09T12:30:00Z
In addition to 510(k) clearance, FemChec, a contrast generating product, is an integral part of the confirmation test following administration of FemBloc non-surgical permanent birth control, currently in late-stage pivotal...
2024-09-09T12:30:00Z
VANCOUVER, Washington, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Dear Shareholders,
2024-09-09T12:30:00Z
VANCOUVER, British Columbia and BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in...
2024-09-09T12:30:00Z
- 2024 unaudited revenue growth for the fiscal fourth quarter and full year of approximately 64% and 148% year-over-year, respectively -
2024-09-09T12:30:00Z
Claude Nicaise, M.D. appointed Chairman of the Board
2024-09-09T12:15:00Z
WARREN, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through...
2024-09-09T12:05:00Z
NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced completion...
2024-09-09T12:01:00Z
MIAMI, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment...
2024-09-09T12:00:59Z
SAN DIEGO and RESEARCH TRIANGLE PARK, N.C., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Creyon Bio, Inc. ("Creyon"), a clinical-stage leader in AI/machine learning-enabled engineering of oligonucleotide-based medicines (OBMs), has appointed...
2024-09-09T12:00:47Z
Presentation of data will take place on Saturday, September 14, 2024
2024-09-09T12:00:00Z
BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells,...
2024-09-09T12:00:00Z
COSTA MESA, CA, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Sauce Essentials (“Sauce” or “the Company”), one of the fastest growing US premium cannabis brands committed to providing top-quality products at affordable...
2024-09-09T12:00:00Z
CHICAGO and FORT WORTH, Texas, Sept. 09, 2024 (GLOBE NEWSWIRE) -- – Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for...
2024-09-09T12:00:00Z
SAN FRANCISCO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc. (“Excision”, the “Company”), a clinical-stage biotechnology company developing CRISPR-based therapies to cure serious latent viral infectious diseases, today announced...
2024-09-09T12:00:00Z
NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the...
2024-09-09T12:00:00Z
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that the...
